We use cookies for a better user experience. Read our Privacy Policy

I Agree

Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market

Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Increased Prevalence of the Infection Drives Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market

The global pipeline analysis of hospital acquired pneumonia drugs market is driven by the rising incidences of nosocomial pneumonia or Hospital-acquired pneumonia.

Hospital-acquired pneumonia (HAP) or nosocomial pneumonia is one of the leading reasons for mortality and morbidity despite the existence of improved supportive care, antimicrobial, and prevention therapy.

Hospital-acquired pneumonia or nosocomial pneumonia is any pneumonia that is acquired by a patient in the settings of a hospital at least after 48 to 72 hours of being admitted. It is, as such, is much different from community-acquired pneumonia. Generally, bacterial infection rather than a viral one causes hospital-acquired pneumonia. A patient suffering from hospital-acquired pneumonia usually exhibits a combination of leukocytosis or leucopenia, poor oxygenation, hypothermia or fever, and augmented tracheal secretions.

Multidrug Resistance of Hospital-acquired Pneumonia Causing Bacteria Fuels Growth

Nosocomial or hospital acquired pneumonia gives rise to several complications and create complicate the medical condition for patients admitted in hospitals across the globe. Multidrug resistant microorganisms are responsible for the occurrence of these infections. These infections considerably diminish the patient’s ability to recuperate and numerous comorbidities also follow, which is likely to support growth of the global pipeline analysis of hospital acquired pneumonia drugs market in the years to come.

Some of the symptoms of hospital-acquired pneumonia comprise the following

  • A cough with pus-like or greenish phlegm (sputum)
  • Chills and fever
  • Loss of appetite
  • Vomiting and nausea
  • Sharp pain in the chest pain that gets worse with deep breathing or coughing
  • Shortness of breath
  • General discomfort, uneasiness, or ill feeling (malaise)
  • Fast heart rate and decreased blood pressure and

These organisms, being multidrug resistant, are immune to the usual antibiotics. Multidrug resistance makes it difficult for the conventional antibiotics to treat the infection acquired in the hospital, which is expected to boost the global pipeline analysis of hospital acquired pneumonia drugs market. Pneumonia is considered one of the most prominent infections caused in the premises of a hospital. Incidences of hospital-acquired pneumonia are quite high in the elderly and infant patients, immunocompromised patients. It also attacks patients going through enteral feeding and in post surgical infections.

Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne.  

Currently there are four drugs authorized for treatment of hospital acquired pneumonia; these include Zosyn (piperacillin/tazobactam), Zyvox (linezolid), Tygacil (tigecycline), and Vibativ (telavancin). Consistent research and development is being conducted in view of introducing more effective treatment options. There are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage, which mainly include biological drugs. 

Tedizolid phosphate and ceftolozane/tazobactam by Cubist Pharmaceutical, ceftazidime/avibactam by AstraZeneca PLC, amikacin inhale by Bayer Healthcare, plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline are the phase III candidates. Considering the antibacterial efficiency, and current market competition, tedizolid phosphate is expected to be the most preferred drug for treatment of nosocomial pneumonia. Amikacin inhale, an aerosolized drug is intended for sale as a drug device combination. Majority of the drugs in the late stages are biological drugs. Aridis Pharmaceutical holds four investigational drugs against various causative agents of hospital acquired pneumonia, each being monoclonal antibody therapy. 

Key companies in the market include Achaogen, Inc., Aridis Pharmaceutical, AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer Healthcare, Cubist Pharmaceutical, GlaxoSmithKline, Meiji Seika Pharma Co., Ltd., Merck & Co., and Valneva SE.

Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Secondary Research
      1.3.2 Primary Research
1.4 List of Abbreviations
1.5 Assumptions
 
Chapter 2 Executive Summary
2.1.1 Hospital Acquired Pneumonia Phase III Candidates, Market Share, 2020 (Value %)
 
Chapter 3 Market overview
3.1 Introduction
      3.1.1 Types of Nosocomial Pneumonia
               3.1.1.1 Bacterial pneumonia
               3.1.1.2 Viral pneumonia
      3.1.2 Epidemiology of hospital acquired pneumonia
      3.1.3 Diagnosis of hospital acquired pneumonia
      3.1.4 Treatment of hospital acquired pneumonia
3.2 Market Dynamics
      3.2.1 Market Drivers
              3.2.1.1 Rising drug resistance among infectious microorganisms increasing chances of hospital acquired infections
              3.2.1.2 Inefficient sterilization and unhygienic conditions in low and middle income countries increasing prevalence of hospital acquired infections
                         3.2.1.2.1 Prevalence of hospital acquired infections in developed and developing countries
      3.2.2 Market Restraints
              3.2.2.1 Government scrutinizing hospital policies to curb hospital-acquired infections
      3.2.3 Market Opportunities
              3.2.3.1 Promising future for vaccines in the nosocomial pneumonia market
              3.2.3.2 Potential for research in vaccine development for causative agents other than S. pneumonia
3.3 Event Impact Analysis
      3.3.1 Event Impact Analysis: Hospital Acquired Pneumonia Market
3.4 Value Chain Analysis
      3.4.1 Value Chain Analysis
3.5 Porter’s Five Forces Analysis for the Global Hospital Acquired Pneumonia Drugs Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Porter’s Five Forces Analysis: Global Hospital Acquired Pneumonia Market
      3.5.3 Bargaining Power of Buyers
      3.5.4 Threat of Substitutes
      3.5.5 Threat of New Entrants
      3.5.6 Competitive Rivalry
3.6 Market Analysis of Major Drugs and Vaccines for Hospital Acquired Pneumonia
      3.6.1 Revenue trend of major branded drugs and vaccines in nosocomial pneumonia market (USD Million)
 
Chapter 4 Hospital Acquired Pneumonia, Pipeline Analysis
4.1 Introduction
4.2 Late Stage (Phase III)
      4.2.1 Tedizolid phosphate
               4.2.1.1 Global Tedizolid Phosphate Market Revenue, 2017 – 2020 (USD million)
      4.2.2 Ceftolozane/Tazobactam
              4.2.2.1 Global Ceftolozane/Tazobactam Market Revenue, 2017 – 2020 (USD million)
      4.2.3 Ceftazidime/Avibactum
              4.2.3.1 Global Ceftazidime/Avibactam Market Revenue, 2017 – 2020 (USD Million)
      4.2.4 Amikacin Inhale
              4.2.4.1 Global Amikacin Inhale Market Revenue, 2016 – 2020 (USD Million)
      4.2.5 Plazomicin
              4.2.5.1 Global Plazomicin Market Revenue, 2017 – 2020 (USD Million)
      4.2.6 Synflorix Vaccine
              4.2.6.1 Global Synflorix Market Revenue, 2012 – 2020 (USD Million)
4.3 Early Stage (Phase I and II)
      4.3.1 BAL30072
      4.3.2 MEDI4893
      4.3.3 AR-301 or KBSA301
      4.3.4 AR-101 (or KBPA101) and AR-104 (or KBPA104)
      4.3.5 AR-201 (or KBRV201)
      4.3.6 AR-401 (or KBAB401)
      4.3.7 ME1100
      4.3.8 GSK 2189242A
      4.3.9 V114
      4.3.10 IC43
 
Chapter 5 Global Pipeline Review of Hospital Acquired Pneumonia Drugs Market, by Geography
5.1 Introduction
5.2 North America
5.3 Europe
5.4 Asia Pacific
5.5 Rest of the World
 
Chapter 6 Recommendations
6.1 Research and development for biological drugs
6.2 Mergers, acquisitions and strategic agreements
 
Chapter 7 Company Profiles
7.1 Achaogen, Inc.
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 Aridis Pharmaceuticals
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 AstraZeneca plc
      7.3.1 Company Profile
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 Cubist Pharmaceuticals, Inc.
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
7.5 Meiji Seika Pharma Co. Ltd.
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio
      7.5.4 Business Strategies
      7.5.5 Recent Developments
7.6 Merck & Co. Inc.
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Product Portfolio
      7.6.4 Business Strategies
      7.6.5 Recent Developments
7.7 Sanofi
      7.7.1 Company Overview
      7.7.2 Financial Overview
      7.7.3 Product Portfolio
      7.7.4 Business Strategies
      7.7.5 Recent Developments
7.8 GlaxoSmithKline, Inc.
      7.8.1 Company Overview
      7.8.2 Financial Overview
      7.8.3 Product Portfolio
      7.8.4 Business Strategies
      7.8.5 Recent Developments
7.9 Valneva SE
      7.9.1 Company Overview
      7.9.2 Financial Overview
      7.9.3 Product Portfolio
      7.9.4 Business Strategies
      7.9.5 Recent Developments
List of Tables
 
TABLE 1 Nosocomial Pneumonia Drugs and Vaccines, Market Snapshot
TABLE 2 Investigational Candidates for Nosocomial Pneumonia Treatment
TABLE 3 Prevalence of Hospital Acquired Infections in Developed and Developing Countries
TABLE 4 Event Impact Analysis, Hospital Acquired Pneumonia Market
 
List of Figures
 
FIG. 1 Hospital Acquired Pneumonia: Drug Pipeline
FIG. 2 Hospital Acquired Pneumonia Phase III Candidates, Market Share, 2020 (Value %)
FIG. 3 Value Chain Analysis
FIG. 4 Porter’s Five Forces Analysis: Global Hospital Acquired Pneumonia Market
FIG. 5 Revenue trend of major branded drugs and vaccines in nosocomial pneumonia market (USD Million)
FIG. 6 Global Tedizolid Phosphate Market Revenue, 2017 – 2020 (USD Million)
FIG. 7 Global Ceftolozane/Tazobactam Market Revenue, 2017 – 2020 (USD million)
FIG. 8 Global Ceftazidime/Avibactam Market Revenue, 2017 – 2020 (USD Million)
FIG. 9 Global Amikacin Inhale Market Revenue, 2016 – 2020 (USD Million)
FIG. 10 Global Plazomicin Market Revenue, 2017 – 2020 (USD Million)
FIG. 11 Global Synflorix Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 AstraZeneca PLC: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 13 Cubist Pharmaceuticals, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 14 Meiji Holdings, Co. Ltd., Pharmaceutical Segment.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 15 Merck & Co. Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 16 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 17 GlaxoSmithKline, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

186

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved